Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2016 Dec 12;16(2):323–333. doi: 10.1158/1535-7163.MCT-16-0501

Figure 6. c-CPE-NP encapsulating the p16 DT-A plasmid are effective in inhibiting ovarian tumor growth in vivo.

Figure 6

Mice harboring subcutaneous OSPC ARK-1 derived chemotherapy-resistant ovarian cancer were treated IP with multiple doses of c-CPE-NP encapsulating the p16 DT-A plasmid starting one week after tumor implantation. Tumor sizes and mouse weights were monitored over the course of the entire experiment twice a week. (A) Treatment of mice with c-CPE-NP encapsulating the p16 DT-A plasmid significantly reduced tumor growth compared to controls including mice injected with the vehicle (ie, PBS) and mice treated with the same doses of c-CPE-NP encapsulating the empty plasmid. (B) No significant major organ toxicity or weight loss in mice was reported over the entire course of the study.